Peptides Similar to Pramlintide (Symlin)
Compare Pramlintide (Symlin) with related peptides and alternatives
📌TL;DR
- •3 similar peptides identified
- •Cagrilintide: Very high - Both are synthetic amylin analogs that activate amylin receptors for glucose regulation and satiety, but with vastly different pharmacokinetics
- •Semaglutide: Moderate - Both are injectable peptides for diabetes with weight loss benefits, but they target different receptors and hormonal pathways
Quick Comparison
| Peptide | Similarity | Key Differences |
|---|---|---|
| Pramlintide (Symlin) (current) | - | - |
| Cagrilintide | Very high - Both are synthetic amylin analogs that activate amylin receptors for glucose regulation and satiety, but with vastly different pharmacokinetics | Cagrilintide is a long-acting amylin analog with a ~7-day half-life (weekly dosing) achieved through fatty acid acylation. Pramlintide has a ~48-minute half-life requiring injection before each meal. Cagrilintide is being developed primarily for obesity (as part of CagriSema with semaglutide), while pramlintide is approved for diabetes. |
| Semaglutide | Moderate - Both are injectable peptides for diabetes with weight loss benefits, but they target different receptors and hormonal pathways | Semaglutide is a GLP-1 receptor agonist (weekly) while pramlintide is an amylin analog (before each meal). Semaglutide produces much greater weight loss and HbA1c reduction. They work through distinct but complementary mechanisms. |
| Liraglutide | Moderate - Both are daily injectable peptides for diabetes, though they target different receptors | Liraglutide is a GLP-1 receptor agonist (once daily) while pramlintide is an amylin analog (before each meal). Liraglutide has greater overall efficacy for HbA1c and weight loss. Both slow gastric emptying but through different mechanisms. |
CagrilintideVery high - Both are synthetic amylin analogs that activate amylin receptors for glucose regulation and satiety, but with vastly different pharmacokinetics
Differences
Cagrilintide is a long-acting amylin analog with a ~7-day half-life (weekly dosing) achieved through fatty acid acylation. Pramlintide has a ~48-minute half-life requiring injection before each meal. Cagrilintide is being developed primarily for obesity (as part of CagriSema with semaglutide), while pramlintide is approved for diabetes.
Advantages
Pramlintide is FDA-approved with 19+ years of clinical experience for both T1D and T2D; established safety profile; available commercially
Disadvantages
Very short half-life requiring 2-3 daily injections; modest efficacy compared to emerging amylin analogs; high injection burden limits adoption
SemaglutideModerate - Both are injectable peptides for diabetes with weight loss benefits, but they target different receptors and hormonal pathways
Differences
Semaglutide is a GLP-1 receptor agonist (weekly) while pramlintide is an amylin analog (before each meal). Semaglutide produces much greater weight loss and HbA1c reduction. They work through distinct but complementary mechanisms.
Advantages
Semaglutide has far greater HbA1c reduction and weight loss, weekly dosing, oral formulation, proven CV benefit (SELECT), and multiple FDA-approved indications
Disadvantages
Semaglutide does not replace deficient amylin; higher GI side effect rates at weight-loss doses; does not specifically address postprandial glucose excursions the way amylin replacement does
LiraglutideModerate - Both are daily injectable peptides for diabetes, though they target different receptors
Differences
Liraglutide is a GLP-1 receptor agonist (once daily) while pramlintide is an amylin analog (before each meal). Liraglutide has greater overall efficacy for HbA1c and weight loss. Both slow gastric emptying but through different mechanisms.
Advantages
Liraglutide has greater efficacy, once-daily dosing, proven CV benefit (LEADER trial), pediatric obesity approval, and broader clinical evidence
Disadvantages
Liraglutide requires daily injection (though less frequent than pramlintide); does not address amylin deficiency; may be less effective for postprandial glucose spikes in T1D
Peptides Related to Pramlintide#
Pramlintide (Symlin) is the only FDA-approved amylin analog, occupying a unique niche as amylin replacement therapy. Its closest relatives are next-generation amylin analogs, while its therapeutic comparators are the GLP-1 receptor agonists that dominate the diabetes and obesity market.
Cagrilintide#
Cagrilintide is the most directly comparable peptide to pramlintide, as both are synthetic amylin analogs targeting the same receptor system. However, cagrilintide represents a generational leap in amylin pharmacology. Through fatty acid acylation, cagrilintide achieves a ~7-day half-life compared to pramlintide's ~48 minutes, enabling once-weekly dosing. Cagrilintide is being developed in combination with semaglutide (CagriSema) for obesity, a combination that leverages the complementary mechanisms of amylin and GLP-1 receptor activation.
Semaglutide (Ozempic / Wegovy)#
Semaglutide works through an entirely different mechanism (GLP-1 receptor agonism) but shares therapeutic overlap with pramlintide in diabetes management. While semaglutide produces far greater HbA1c reduction and weight loss, pramlintide may offer specific advantages for postprandial glucose control in type 1 diabetes, a population where GLP-1 agonists have limited approved indications. The combination of amylin and GLP-1 pathways (as exemplified by CagriSema) suggests these approaches are complementary rather than competing.
Liraglutide (Victoza / Saxenda)#
Liraglutide is the daily GLP-1 agonist most analogous to pramlintide in terms of injection frequency (though liraglutide is once daily vs pramlintide's 2-3 times daily). Both slow gastric emptying and promote weight loss, but through different receptor pathways.
Summary Comparison#
| Feature | Pramlintide | Cagrilintide | Semaglutide | Liraglutide |
|---|---|---|---|---|
| Target | Amylin receptor | Amylin receptor | GLP-1 receptor | GLP-1 receptor |
| Dosing | Before each meal | Weekly | Weekly or daily oral | Daily |
| Half-life | ~48 minutes | ~7 days | ~7 days | ~13 hours |
| HbA1c reduction | -0.5 to -0.7% | TBD | -1.5 to -2.2% | -1.1 to -1.2% |
| Weight effect | -1 to -2 kg | Significant | Significant | Moderate |
| Regulatory status | Approved (2005) | Phase 3 | Approved | Approved |
Comparison Context#
Pramlintide (Symlin) belongs to the Metabolic category of research peptides. Comparing Pramlintide (Symlin) with related compounds helps researchers understand its relative positioning in the therapeutic landscape. Each compound has distinct advantages and limitations that should be considered based on the specific research question or clinical need.
Detailed Comparisons#
The following peptides and compounds are most closely related to Pramlintide (Symlin) in mechanism, indication, or therapeutic category:
Pramlintide (Symlin) vs Cagrilintide#
Similarity: Very high - Both are synthetic amylin analogs that activate amylin receptors for glucose regulation and satiety, but with vastly different pharmacokinetics
Key Differences: Cagrilintide is a long-acting amylin analog with a ~7-day half-life (weekly dosing) achieved through fatty acid acylation. Pramlintide has a ~48-minute half-life requiring injection before each meal. Cagrilintide is being developed primarily for obesity (as part of CagriSema with semaglutide), while pramlintide is approved for diabetes.
Advantages of Cagrilintide: Pramlintide is FDA-approved with 19+ years of clinical experience for both T1D and T2D; established safety profile; available commercially
Disadvantages of Cagrilintide: Very short half-life requiring 2-3 daily injections; modest efficacy compared to emerging amylin analogs; high injection burden limits adoption
Researchers choosing between Pramlintide (Symlin) and Cagrilintide should consider the development stage, available evidence, and specific research objectives when making their selection.
Pramlintide (Symlin) vs Semaglutide#
Similarity: Moderate - Both are injectable peptides for diabetes with weight loss benefits, but they target different receptors and hormonal pathways
Key Differences: Semaglutide is a GLP-1 receptor agonist (weekly) while pramlintide is an amylin analog (before each meal). Semaglutide produces much greater weight loss and HbA1c reduction. They work through distinct but complementary mechanisms.
Advantages of Semaglutide: Semaglutide has far greater HbA1c reduction and weight loss, weekly dosing, oral formulation, proven CV benefit (SELECT), and multiple FDA-approved indications
Disadvantages of Semaglutide: Semaglutide does not replace deficient amylin; higher GI side effect rates at weight-loss doses; does not specifically address postprandial glucose excursions the way amylin replacement does
Researchers choosing between Pramlintide (Symlin) and Semaglutide should consider the development stage, available evidence, and specific research objectives when making their selection.
Pramlintide (Symlin) vs Liraglutide#
Similarity: Moderate - Both are daily injectable peptides for diabetes, though they target different receptors
Key Differences: Liraglutide is a GLP-1 receptor agonist (once daily) while pramlintide is an amylin analog (before each meal). Liraglutide has greater overall efficacy for HbA1c and weight loss. Both slow gastric emptying but through different mechanisms.
Advantages of Liraglutide: Liraglutide has greater efficacy, once-daily dosing, proven CV benefit (LEADER trial), pediatric obesity approval, and broader clinical evidence
Disadvantages of Liraglutide: Liraglutide requires daily injection (though less frequent than pramlintide); does not address amylin deficiency; may be less effective for postprandial glucose spikes in T1D
Researchers choosing between Pramlintide (Symlin) and Liraglutide should consider the development stage, available evidence, and specific research objectives when making their selection.
Related Reading#
Frequently Asked Questions About Pramlintide (Symlin)
Explore Further
Disclaimer: For educational purposes only. Not medical advice. Read full disclaimer